Sosei Heptares Creates New World-Class International Scientific Advisory Board to Support Strategic Decision-Making Aligned with Corporate Objectives - Seite 2

Dr. Caetano Reis e Sousa, Assistant Research Director and Senior Group Leader of the Immunobiology Laboratory at The Francis Crick Institute and Professor of Immunology at Imperial College London.

Dr. Darryle Schoepp, a research consultant with over 30 years' experience in the discovery and development of innovative neuroscience therapeutics leading research and therapeutic area teams at Eli Lilly and Merck & Co.

Dr. Roberto Solari, Visiting Professor at the National Heart & Lung Institute (Imperial College London); formerly at GlaxoSmithKline and MRCT, the technology transfer arm of the UK Medical Research Council.

Dr. Christopher Tate, a membrane protein biochemist at the MRC LMB who pioneered the use of conformational thermostabilization for the structure determination of GPCRs; co-founder of Heptares Therapeutics.

Mr. Anders Tullgren, a consultant/advisor to pharmaceutical and biotechnology companies and private equity firms; over 20 years in commercial leadership roles at Bristol-Myers Squibb around the world.

Dr. Malcolm Weir, Executive Vice President Research and Early Development of Sosei Heptares, said: "We are delighted to have assembled such an outstanding Scientific Advisory Board. Each member has been selected based on the world-class expertise and experience they can bring to support our scientific strategy as a fundamental driver of our corporate activities. Their insights and advice will be crucial to our strategic decision-making processes as we continue to create value from our leading GPCR-focused drug discovery and development capabilities."

About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications.

We have established partnerships with some of the world's leading pharmaceutical companies, including Allergan, AstraZeneca, Daiichi-Sankyo, Genentech (Roche), Novartis, Pfizer and Takeda; and with innovative biotechnology companies, including Kymab, MorphoSys and PeptiDream. Sosei Heptares is headquartered in Tokyo, Japan with R&D facilities in Cambridge, UK.